Turning Point Therapeutics, Inc.Consulting Agreement • February 28th, 2022 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations
This letter sets forth the terms of the transition consulting agreement (the “Consulting Agreement”) that Turning Point Therapeutics, Inc. (the “Company”) is offering to you in connection with your resignation from the Company effective as of March 4, 2022 (“Separation Date”).
CLINICAL TRIAL COLLABORATION AGREEMENTClinical Trial Collaboration Agreement • February 28th, 2022 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations
This CLINICAL TRIAL COLLABORATION AGREEMENT (this “Agreement”), dated as of October 13, 2021 (the “Effective Date”), is by and between EQRx, Inc., a Delaware corporation having a place of business at 50 Hampshire Street, Cambridge, MA 02139 (“EQRx”), and Turning Point Therapeutics, Inc., a Delaware corporation having a place of business at 10628 Science Center Drive, Suite 200, San Diego, CA 92121 (“TPT”). EQRx and TPT are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
